Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

AbbVie ABBV has been expanding its oncology portfolio over the past few years. While the company was originally focused on ...

Amgen combines patent protection, a robust pipeline, and strong execution for defensive investment. Click here to read an ...

Seven biotech unicorns are advancing AI-powered drug discovery and development—but must contend with a difficult investing ...

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Organon ...

Eli Lilly & Co. closed 20.65% short of its 52-week high of $972.53, which the company achieved on August 22nd.

While Leerink still expects Zoetis to post revenue and earnings growth, it sees the pace decelerating as rivals like Elanco and Merck (NSE: PROR) gain share. The firm forecasts Zoetis EPS growth to ...

Eli Lilly’s stock closed at $771.75, slipping 3.45% and lagging the broader market. The company’s shares fell despite ...

Global Disruptive Behavior Disorders (DBD) Market is valued approximately at USD 14.83 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 3.31% over the forecast period ...